Abstract:Abstract Background Liver ischemia/reperfusion (I/R) injury is an inevitable pathological phenomenon in various clinical conditions, such as liver transplantation, resection surgery, or shock, which is the major cause of morbidity and mortality after operation. Ginkgo Biloba Dropping Pill (GBDP) is a unique Chinese Ginkgo Biloba leaf extract preparation that exhibits a variety of beneficial biological activities. The aim of this study is to investigate the protective effects of GBDP on the liver I/R injury both in the in vitro and in vivo. Methods Hypoxia/reoxygenation (H/R) experiments were performed in alpha mouse liver 12 (AML-12) cells and primary hepatocytes, which were pretreated with GBDP (60 or 120 µg/mL) followed by incubation in a hypoxia chamber. Cell viability was detected by 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay. Annexin V staining as well as western blot analysis of apoptosis-related proteins was performed to detect the protective effect of GBDP on cell apoptosis induced by H/R injury. C57BL/6 mice were used to establish the liver I/R injury model, and were pretreated with GBDP (100 or 200 mg/kg/day, i.g.) for two weeks. The liver damage was evaluated by detection of plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST), as well as histopathological examinations. Liver inflammation was determined by detecting the secretion of pro-inflammatory cytokines and neutrophil infiltration through enzyme-linked immunosorbent assay (ELISA) and myeloperoxidase (MPO) immunohistochemistry staining. Finally, Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick and labeling (TUNEL) staining and western blot analysis of apoptosis-related proteins were used to investigate the anti-apoptotic effect of GBDP in mice. Results In the in vitro study, GBDP pretreatment improved the cell viability of AML-12 cells in the H/R injury model. Similarly, the same result was found in the primary hepatocytes isolated from C57BL/6 mice. Moreover, GBDP decreased the number of apoptotic cells and reduced the expression of apoptosis-related proteins induced by H/R injury. In the in vivo study, oral administration of GBDP ameliorated liver injury evidenced by a significant decline in the levels of ALT and AST. Furthermore, the result of hematoxylin and eosin (H&E) staining showed that GBDP reduced the size of necrosis area in the liver tissue. In addition, the decreased infiltration of neutrophils and secretion of pro-inflammatory cytokines indicated that GBDP may play an anti-inflammatory effect. More importantly, GBDP reduced TUNEL-positive cells and the expression of apoptosis-related proteins in the liver indicating GBDP has anti-apoptotic effects. Conclusions Our findings elucidated that GBDP has potential effects for protecting against liver I/R injury characterized by its anti-apoptotic, anti-necrotic, and anti-inflammatory properties, which would promisingly make contributions to the exploration of therapeutic strategies in the liver I/R injury.

Inhibition of Glycogen Synthase Kinase 3 Ameliorates Liver Ischemia/reperfusion Injury Via an Energy-Dependent Mitochondrial Mechanism.

Inhibition of Glycogen Synthase Kinase 3β Protects Liver Against Ischemia/reperfusion Injury by Activating 5′ Adenosine Monophosphate‐activated Protein Kinase‐mediated Autophagy

Inhibition Of Glycogen Synthase Kinase 3 Beta Protects Liver Against Ischemia/Reperfusion Injury By Activating 5 ' Adenosine Monophosphate-Activated Protein Kinase-Mediated Autophagy

Inhibition of GSK3 beta protects liver against ischemia/reperfusion injury via activating AMPK-mediated autophagy

Inhibition of GSK-3β Ameliorates Hepatic Ischemia-Reperfusion Injury Through GSK-3β/β-catenin Signaling Pathway in Mice

Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice

Inhibition of Glycogen Synthase Kinase 3 Beta Ameliorates Liver Ischemia Reperfusion Injury by Way of an Interleukin-10-mediated Immune Regulatory Mechanism.

Glycogen synthase kinase-3β: A multifaceted player in ischemia-reperfusion injury and its therapeutic prospects

Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload

Ischemic Preconditioning Increases Gsk-3 Beta/Beta-Catenin Levels And Ameliorates Liver Ischemia/Reperfusion Injury In Rats

Role of glycogen synthase kinase 3β in protective effect of propofol against hepatic ischemia-reperfusion injury.

Hepatocyte Gsk3 Inactivation Via Phosphorylations is Essential for Ischemia Reperfusion Induced Inflammatory Cell Death.

Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production

Pre‐conditions for Eliminating Mitochondrial Dysfunction and Maintaining Liver Function after Hepatic Ischaemia Reperfusion

The age-associated decline of glycogen synthase kinase 3beta plays a critical role in the inhibition of liver regeneration

Pre-conditions for eliminating mitochondrial dysfunction and maintaining liver function after hepatic ischaemia reperfusion

Effect of Propofol Pretreatment Against Hepatic Ischemia-Reperfusion Injury on Mitochondrial Permeability Transition Pore in Rats

Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration

Role of GSK-3β in the Protective Effect of Propofol Pretreatment Against Hepatic Ischemia-Reperfusion Injury and Oxidative Stress in Rats

Protective Effects of Ginkgo Biloba Dropping Pills Against Liver Ischemia/reperfusion Injury in Mice

Activation of Nrf2/HO-1 Pathway by Glycogen Synthase Kinase-3β Inhibition Attenuates Renal Ischemia/Reperfusion Injury in Diabetic Rats